BOCA RATON, FL - INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage immunology company, announced significant improvements in brain function in patients with moderate to severe Alzheimer's Disease (AD) after four weeks of treatment with their drug candidate XPro™.
The treatment demonstrated a statistically significant increase in Alpha wave frequency and power, which are associated with cognitive functions and have been found to decline with the progression of Alzheimer's.
The seven-patient pilot study utilized electroencephalography (EEG), a measure of brain activity, to evaluate the effects of XPro™, a dominant-negative inhibitor of soluble TNF, on brain function. The promising results add to previous Phase 1 findings that XPro™ reduced inflammation markers and improved indicators of neurodegeneration and synaptic function.
Dr. CJ Barnum, VP of Neuroscience at INmune Bio, emphasized the importance of functional benefits as a benchmark for drug efficacy and indicated that the company is conducting a Phase 2 placebo-controlled trial to further substantiate these findings.
Cumulus Neuroscience's innovative, FDA-approved, portable EEG device was used to facilitate the use of EEG as a regular measure in clinical trials. Dr. Brian Murphy, Chief Scientific Officer of Cumulus Neuroscience, highlighted the potential of task-synchronized EEG in drug development for Alzheimer's Disease.
INmune Bio is focused on targeting the innate immune system to fight disease, with XPro™ being the first of several DN-TNF products in clinical trials for conditions such as Mild Alzheimer's Disease, treatment-resistant depression, and oncology. The company also has a Natural Killer Cell Priming Platform, with INKmune™ currently in a Phase I/II trial for metastatic castrate resistant prostate cancer.
The recent findings underscore the potential of EEG as a biomarker for brain function in AD research and treatment evaluation. However, it is important to note that these clinical trials are in the early stages and the outcomes are not guaranteed.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.